Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

NCT ID: NCT02226172

Last Updated: 2019-01-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-06
• Study Completion Date: 2018-01-31

Brief Summary

A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to ruxolitinib.

Conditions

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Arm A

Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.

Group Type: EXPERIMENTAL

Glasdegib (PF-04449913)

Intervention Type: DRUG

Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.

Arm B

Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.

Interventions

Glasdegib (PF-04449913)

Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.

Intervention Type: DRUG

Placebo

Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of primary MF (PMF) or secondary MF (PET-MF and PPV-MF) as per WHO 2008 criteria.
• Lead-in cohort: resistant or intolerant to 1 or more Janus kinase inhibitors (licensed or experimental).
• Randomized cohort: resistant or intolerant to prior ruxolitinib therapy. Documentation by the Investigator that the patient has exhausted available treatment options (eg, resistant or intolerant to hydroxyurea, etc).
• Spleen 5 cm below the inferior left costal margin as measured by manual palpation.
• Active symptomatic MF as defined by the screening MPN-SAD patient-reported instrument requiring a severity score of at least 5 on one symptom, or a severity score of ≥ 3 on at least two of the symptoms (on a 0 to 10 scale).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3.
• Adequate organ function, demonstrated by the following laboratory values:

1. Absolute Neutrophil Count 75 x 10(9)/L;

2. Platelet count >50 x 10(9)/L with no evidence of bleeding and not requiring platelet transfusions;

3. Serum creatinine <1.5 x upper limit of normal (ULN) or estimated creatinine clearance 60 mL/min (as calculated using the standard method of the institution);

4. Serum amylase or lipase <1.5 x ULN;

5. Aspartate aminotransferase and alanine aminotransferase values 3.0 x ULN (or 5x ULN in the case of patients with MF accompanied by hepatic extramedullary hematopoiesis, as manifested by any degree of hepatomegaly).

6. Total bilirubin values <1.5 x ULN unless the bilirubin is principally unconjugated (in the context of hemolysis) or there is documented Gilbert's disease.

7. Serum electrolyte values < Grade 2 (sodium, potassium, calcium, phosphorous and magnesium), per CTCAE v.4.03.

• Recovery to Grade 1 from all clinically significant adverse events related to prior MF therapy, including transplant-related toxicities.
• More than 2 months out from allogenic hematopoietic stem cell transplant prior to randomization.
• Must be able to undergo MRI of abdomen (spleen and liver). Patients who are contra indicated for MRI may be enrolled and evaluated by CT scan at the discretion of the Sponsor.
• 18 years of age.
• Male subjects able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use two highly effective methods of contraception throughout the study and for 90 days after the last dose of assigned treatment.

Exclusion Criteria

• Prior treatment with a licensed or experimental smoothened inhibitor.
• Randomized cohort only: Prior treatment with a Janus kinase inhibitor other than ruxolitinib.
• Other anti-cancer therapy up to 14 days prior to enrollment, with the exception of hydroxyurea, which can be given up to 4 days prior to enrollment.
• Splenic irradiation 3 months prior to enrollment.
• History of congenital long QT syndrome, or a baseline >470 msec QTcF abnormality (average of the triplicate reading).
• Evidence of significant cardiac disease, for example: symptomatic cardiac heart failure (CHF, NYHA class 3), complete bundle branch block, significant atrial or ventricular tachyarrhythmias and any unstable cardiac arrhythmias requiring medication.
• History of myocardial infarction or unstable angina within 6 months prior to enrollment.
• Uncontrolled inflammatory bowel disease, peptic ulcer disease or history of significant gastro intestinal bleeding within 6 months of enrollment.
• Any condition requiring chronic use of moderate/high dose steroids (equivalent to 10 mg QD prednisone).
• Hematopoietic growth factor receptor agonists (eg, erythropoietin (Epo), granulocyte colony stimulating factor, romiplostim, eltrombopag within 28 days of enrollment.
• Currently active malignancy (other than MF). Prior malignancies are allowed so long as there is no evidence of disease recurrence within the last 2 years (with the exception of fully excised, non-complicated basal cell carcinoma which can have been active within the prior 2 years, and certain localized, non-invasive fully excised skin, cervical, breast, prostate or bladder tumors).
• Prior history of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH]).
• Active, uncontrolled bacterial, fungal or viral infection, including hepatitis B, hepatitis C, known human immunodeficiency virus or acquired immunodeficiency syndrome related illness.
• Active graft versus host disease (GVHD) with other than grade 1 skin involvement or GVHD requiring immunosuppressive treatment.
• Uncontrolled disseminated intravascular coagulation.
• Current (including their administration within 3 days prior to study entry) use or anticipated need for food or drugs that are strong CYP3A4 inhibitors.
• Current use or anticipated requirement for drugs that are known strong CYP3A4/5 inducers.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Mayo Clinic Building - Phoenix

Phoenix, Arizona, United States

Mayo Clinic Hospital

Phoenix, Arizona, United States

Mayo Clinic

Scottsdale, Arizona, United States

UC San Diego Moores Cancer Center - Investigational Drug Services

La Jolla, California, United States

UCSD Medical Center Clinical Laboratory - La Jolla

La Jolla, California, United States

University of California San Diego (UCSD) Moores Cancer Center

La Jolla, California, United States

UC San Diego Medical Center- Hillcrest

San Diego, California, United States

University of Michigan

Ann Arbor, Michigan, United States

Weill Cornell Medical College - New York-Presbyterian Hospital

New York, New York, United States

Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center

New York, New York, United States

Weill Cornell Medical College-New York Presbyterian Hospital

New York, New York, United States

Cleveland Clinic - Taussig Cancer Institute

Cleveland, Ohio, United States

Huntsman Cancer Institute-University of Utah

Salt Lake City, Utah, United States

University of Utah, Huntsman Cancer Hospital

Salt Lake City, Utah, United States

Froedtert Hospital and Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Kobe University Hospital

Kobe, Hyōgo, Japan

Osaka University Hopsital

Suita-Shi, Osaka, Japan

Juntendo University Hospital

Bunkyo-ku, Tokyo, Japan

Tokyo Medical University Hospital

Tokyo, , Japan

Countries

United States; Japan

Related Links

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1371013&StudyName=PF-04449913%20Single-Agent%20In%20Patients%20With%20Myelofibrosis%20Previously%20Treated%20With%20a%20Janus%20Kinase%20Inhibitor

To obtain contact information for a study center near you, click here.

Other Identifiers

SMOI

Identifier Type: OTHER

Identifier Source: secondary_id

2014-000933-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2014-001048-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

B1371013

Identifier Type: -

Identifier Source: org_study_id